Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 399 9500

Website: www.tscan.com

Address:

830 Winter Street, Waltham, United States

soddo40725 Mar. 13 at 8:46 PM

$TCRX lot's of trades AH

0 · Reply

OfficialStocktwitsUser Mar. 13 at 3:40 PM

$TCRX RSI: 56.76, MACD: 0.0267 Vol: 0.07, MA20: 1.07, MA50: 1.08 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

RMND Mar. 13 at 2:27 PM

$TCRX

0 · Reply

topstockalerts Mar. 13 at 1:16 PM

Pre Market Top Gainers $ISPC $ELPW $TCRX $CXAI $EDHL

0 · Reply

soddo40725 Mar. 13 at 12:20 PM

$TCRX let's goooooo ⏰

0 · Reply

Carlosjr1996 Mar. 13 at 11:40 AM

$ISPC $ELPW $TCRX $CXAI $EDHL

0 · Reply

topstockalerts Mar. 13 at 11:39 AM

Pre Market Top Gainers $ISPC $ELPW $TCRX $CXAI $EDHL

0 · Reply

RMND Mar. 12 at 5:24 PM

$TCRX

0 · Reply

SmartMoneyTradez Mar. 10 at 1:40 PM

$TCRX out at break even

0 · Reply

signaljumper Mar. 9 at 8:32 PM

$TCRX looking for 1.74$ Gap Close in the near future . Bullish bottom w formation is finished and active.

1 · Reply

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 7:00 AM EST - 17 days ago

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Feb 25, 2026, 7:00 AM EST - 18 days ago

TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Dec 3, 2025, 4:05 PM EST - 3 months ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

Nov 12, 2025, 7:00 AM EST - 4 months ago

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 4 months ago

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 6:30 AM EST - 4 months ago

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Sep 17, 2025, 7:00 AM EDT - 6 months ago

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Sep 3, 2025, 7:00 AM EDT - 6 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

Aug 12, 2025, 7:00 AM EDT - 7 months ago

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 28, 2025, 7:00 AM EDT - 10 months ago

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 6, 2025, 7:00 AM EDT - 11 months ago

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 4:53 PM EDT - 11 months ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mar 7, 2025, 11:31 AM EST - 1 year ago

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 10, 2025, 3:14 AM EST - 1 year ago

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Dec 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 23, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 9, 2024, 5:45 PM EST - 1 year ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 5, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 2, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Nov 5, 2024, 9:15 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 4, 2024, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Aug 26, 2024, 10:09 AM EDT - 1 year ago

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 12, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Updates to its Board of Directors

May 29, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 13, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Apr 24, 2024, 4:05 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 11:03 AM EDT - 2 years ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 22, 2024, 5:01 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 19, 2024, 10:05 AM EDT - 2 years ago

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 17, 2024, 12:30 AM EDT - 2 years ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 16, 2024, 4:25 PM EDT - 2 years ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:01 PM EDT - 2 years ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 8, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 2, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Jan 29, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Jan 18, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Jan 4, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

soddo40725 Mar. 13 at 8:46 PM

$TCRX lot's of trades AH

0 · Reply

OfficialStocktwitsUser Mar. 13 at 3:40 PM

0 · Reply

RMND Mar. 13 at 2:27 PM

$TCRX

0 · Reply

topstockalerts Mar. 13 at 1:16 PM

Pre Market Top Gainers $ISPC $ELPW $TCRX $CXAI $EDHL

0 · Reply

soddo40725 Mar. 13 at 12:20 PM

$TCRX let's goooooo ⏰

0 · Reply

Carlosjr1996 Mar. 13 at 11:40 AM

$ISPC $ELPW $TCRX $CXAI $EDHL

0 · Reply

topstockalerts Mar. 13 at 11:39 AM

Pre Market Top Gainers $ISPC $ELPW $TCRX $CXAI $EDHL

0 · Reply

RMND Mar. 12 at 5:24 PM

$TCRX

0 · Reply

SmartMoneyTradez Mar. 10 at 1:40 PM

$TCRX out at break even

0 · Reply

signaljumper Mar. 9 at 8:32 PM

$TCRX looking for 1.74$ Gap Close in the near future . Bullish bottom w formation is finished and active.

1 · Reply

SmartMoneyTradez Mar. 9 at 7:39 PM

$EDIT $TCRX nibbled

0 · Reply

RMND Mar. 9 at 4:30 PM

$TCRX

0 · Reply

signaljumper Mar. 5 at 6:38 PM

$TCRX w Formation still in Play, looking very good

0 · Reply

erevnon Mar. 5 at 3:23 PM

Wedbush maintains TScan Therapeutics $TCRX at Outperform and raises the price target from $4 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

anachartanalyst Mar. 5 at 3:02 PM

$TCRX https://anachart.com/wp-content/uploads/ana_temp/1772722902_soc-img.jpg

0 · Reply

d_risk Mar. 4 at 8:23 PM

$TCRX - TScan Therapeutics Inc - 10K - Updated Risk Factors TCRX flags mounting risks from ongoing losses, dependence on its TCR platform and early-stage in vivo solid tumor work, new macro and policy threats from Trump-era tariffs and market volatility, SVB debt default exposure, a major 2025 workforce reduction, growing cybersecurity concerns, and complex, capacity‑constrained manufacturing that it is still learning to run itself. #Biotechnology #EarlyStageResearch #MarketVolatility #CybersecurityRisks #ManufacturingChallenges 🟢 Added 🟠 Removed https://d-risk.ai/TCRX/10-K/2026-03-04

0 · Reply

nshootz Mar. 4 at 4:00 PM

$TCRX Volume picking up. Good info released today

0 · Reply

DARKP00L Mar. 4 at 12:27 PM

$TCRX 07:11 on Mar. 04 2026 TScan Therapeutics' Cash And Cash Equivalents Of $152.4M To Provide Cash Runway Into 2H Of 2027 #tradeideas

0 · Reply

nshootz Mar. 3 at 6:52 PM

$TCRX Bullish Lv2 chart right now

0 · Reply

nshootz Mar. 3 at 4:42 PM

$TCRX Let's get some volume!

0 · Reply

nshootz Mar. 2 at 7:22 PM

$TCRX Conference presentation tomorrow (TD Cow.) @ 11:50a ET

1 · Reply

nshootz Feb. 27 at 9:26 PM

$TCRX Looking forward to this next week!

0 · Reply

Market Cap	59.59M
Revenue (ttm)	10.33M
Net Income (ttm)	-129.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,256.24%
Debt to Equity Ratio	0.26

Volume	650,900
Avg Vol	532,926
Day's Range	N/A - N/A
Shares Out	56.75M
Stochastic %K	22%
Beta	1.03
Analysts	Strong Sell
Price Target	$6.80